Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.78 |
| ▸ | PPARG | P37231 | 3/20 | 0.78 |
| ▸ | PPARD | Q03181 | 3/20 | 0.78 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369617 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL18675574 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL12264930 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL14316094 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL18675576 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL14296866 | 0.85 | ADORA3 (0.86) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL14296862 | 0.84 | ADORA3 (0.77) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL29464001 | 0.84 | ADORA3 (0.78) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL935807 | 0.84 | ADORA3 (0.78) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL935056 | 0.84 | ADORA3 (0.78) | ADORA3ADORA1ADORA2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | OTONOMY, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADORA3 2478/4885ADORA1 2255/4885ADORA2A 2398/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | ADORA3 27/4885ADORA1 31/4885ADORA2A 1/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | ADORA3 2478/4885ADORA1 2255/4885ADORA2A 2398/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | ADORA3 101/4885ADORA1 83/4885ADORA2A 9/4885 |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | PTGIR, HSPH1, HSP90AA1 | ADORA3 3154/4885ADORA1 2686/4885ADORA2A 1279/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.